Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human, Dose-Finding and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of XmAb®808 in Combination With Pembrolizumab in Selected Advanced Solid Tumors

NCT05585034 is registered in ClinicalTrials.gov with Xencor, Inc. as lead sponsor.

NCT NCT05585034
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05585034 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human, Dose-Finding and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of XmAb®808 in Combination With Pembrolizumab in Selected Advanced Solid Tumors
Lead sponsor
Xencor, Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 14, 2022
Completion date
May 20, 2025
Enrollment
60 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate cancer, colorectal cancer, head and neck squamous cell carcinoma, melanoma excluding uveal melanoma, non-small cell lung cancer, squamous or non-squamous, ovarian cancer, epithelial, renal cell carcinoma, clear cell, tnbc - triple-negative breast cancer, urothelial carcinoma